1型糖尿病青少年的自身免疫共病及其与代谢控制和死亡风险的关联:一项基于人群的研究
这项基于瑞典国家糖尿病登记的研究纳入15,188例18岁前发病的1型糖尿病患者,并与74,210名对照匹配。1型糖尿病组19.2%诊断至少一种自身免疫病,对照组为4.0%。自身免疫共病对HbA1c或死亡风险无统计学显著影响。
要点
- 1型糖尿病组19.2%诊断至少一种自身免疫病,对照组为4.0%。
- 乳糜泻和甲状腺病的风险比分别为11.6和10.6。
- 自身免疫共病对HbA1c或死亡风险无统计学显著影响。
核心结论
- 在儿童期已存在较高的自身免疫病患病率,尤其是乳糜泻和甲状腺病。
- 自身免疫共病的存在对代谢控制或死亡风险无统计学显著影响。
研究设计与样本
- 基于登记的研究,纳入瑞典国家糖尿病登记中2000至2019年间18岁前登记的1型糖尿病患者15,188例。
- 从瑞典统计局随机选取5名对照个体与每例1型糖尿病患者匹配,共74,210名对照(346例1型糖尿病患者在诊断日未在统计局登记而无法匹配对照)。
- 使用国家患者登记获取自身免疫病的ICD-10编码,使用死因登记识别死亡个体。
主要发现
- 1型糖尿病队列中,发病平均±标准差年龄为9.5±4.4岁,随访结束时平均病程为8.8±5.7年。
- 1型糖尿病组19.2%诊断至少一种自身免疫病,对照组为4.0%。
- 1型糖尿病发病后19年内共病风险比:乳糜泻11.6(95%CI 10.6, 12.6),甲状腺病10.6(95%CI 9.6, 11.8),银屑病1.3(95%CI 1.1, 1.6),白癜风4.1(95%CI 3.2, 5.3),风湿性关节病1.7(95%CI 1.4, 2.2),炎症性肠病1.0(95%CI 0.8, 1.3),系统性结缔组织病1.0(95%CI 0.7, 1.2),葡萄膜炎1.4(95%CI 1.1, 1.9),艾迪生病18.3(95%CI 8.4, 40.0),多发性硬化1.8(95%CI 0.9, 3.6),炎症性肝病3.7(95%CI 1.6, 8.7),萎缩性胃炎19.6(95%CI 4.2, 92.3)。
- 1型糖尿病之外的自身免疫病对HbA1c或死亡风险无统计学显著影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: This register-based study aimed to describe autoimmune comorbidity in children and young adults from type 1 diabetes onset, and to investigate whether such comorbidity was associated with a difference in HbA1c or mortality risk compared with children/young adults with type 1 diabetes without autoimmune comorbidity. METHODS: A total of 15,188 individuals from the Swedish National Diabetes Register, registered with type 1 diabetes before 18 years of age between 2000 and 2019, were included. Five randomly selected control individuals from the Swedish population (Statistics Sweden) were matched to each individual with type 1 diabetes (n=74,210 [346 individuals with type 1 diabetes were not found in the Statistics Sweden register at the date of type 1 diabetes diagnosis, so could not be matched to control individuals]). The National Patient Register was used to attain ICD-10 codes on autoimmune diseases and the Cause of Death Register was used to identify deceased individuals. RESULTS: In the total type 1 diabetes cohort, mean±SD age at onset of type 1 diabetes was 9.5±4.4 years and mean disease duration at end of follow-up was 8.8±5.7 years. Of the individuals with type 1 diabetes, 19.2% were diagnosed with at least one autoimmune disease vs 4.0% of the control group. The HRs for comorbidities within 19 years from onset of type 1 diabetes were 11.6 (95% CI 10.6, 12.6) for coeliac disease, 10.6 (95% CI 9.6, 11.8) for thyroid disease, 1.3 (95% CI 1.1, 1.6) for psoriasis, 4.1 (95% CI 3.2, 5.3) for vitiligo, 1.7 (95% CI 1.4, 2.2) for rheumatic joint disease, 1.0 (95% CI 0.8, 1.3) for inflammatory bowel disease, 1.0 (95% CI 0.7, 1.2) for systemic connective tissue disorder, 1.4 (95% CI 1.1, 1.9) for uveitis, 18.3 (95% CI 8.4, 40.0) for Addison's disease, 1.8 (95% CI 0.9, 3.6) for multiple sclerosis, 3.7 (95% CI 1.6, 8.7) for inflammatory liver disease and 19.6 (95% CI 4.2, 92.3) for atrophic gastritis. Autoimmune disease in addition to type 1 diabetes had no statistically significant effect on HbA1c or mortality risk. CONCLUSIONS/INTERPRETATION: To our knowledge, this is the first comprehensive study where young individuals with type 1 diabetes were followed regarding development of a wide spectrum of autoimmune diseases, from onset of type 1 diabetes. In this nationwide and population-based study, there was already a high prevalence of autoimmune diseases in childhood, especially coeliac and thyroid disease. The presence of autoimmune comorbidity did not have a statistically significant effect on metabolic control or mortality risk.
引用
- Samuelsson J, Bertilsson R, Bülow E, et al. Autoimmune comorbidity in type 1 diabetes and its association with metabolic control and mortality risk in young people: a population-based study. Diabetologia. 2024. PMID: 38252314. doi:10.1007/s00125-024-06086-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。